<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35431658</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1523-3847</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Current infectious disease reports</Title><ISOAbbreviation>Curr Infect Dis Rep</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Infection in Children: Diagnosis and Management.</ArticleTitle><Pagination><StartPage>51</StartPage><EndPage>62</EndPage><MedlinePgn>51-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11908-022-00779-0</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="UNASSIGNED">Due to the rapidly changing landscape of COVID-19, the purpose of this review is to provide a concise and updated summary of pediatric COVID-19 diagnosis and management.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="UNASSIGNED">The relative proportion of pediatric cases have significantly increased following the emergence of the Omicron variant (from&#x2009;&lt;&#x2009;2% in the early pandemic to 25% from 1/27 to 2/3/22). While children present with milder symptoms than adults, severe disease can still occur, particularly in children with comorbidities. There is a relative paucity of pediatric data in the management of COVID-19 and the majority of recommendations remain based on adult data.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="UNASSIGNED">Fever and cough remain the most common clinical presentations, although atypical presentations such as "COVID toes," anosmia, and croup may be present. Children are at risk for post-infectious complications such as MIS-C and long COVID. Nucleic acid amplification tests through respiratory PCR remain the mainstay of diagnosis. The mainstay of management remains supportive care and prevention through vaccination is highly recommended. In patients at increased risk of progression, interventions such as monoclonal antibody therapy, PO Paxlovid, or IV remdesivir&#x2009;&#xd7;&#x2009;3&#xa0;days should be considered. In patients with severe disease, the use of remdesivir, dexamethasone, and immunomodulatory agents (tocilizumab, baricitinib) is recommended. Children can be at risk for thrombosis from COVID-19 and anticoagulation is recommended in children with markedly elevated D-dimer levels or superimposed clinical risk factors for hospital associated venous thromboembolism.</AbstractText><CopyrightInformation>&#xa9; The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0644-3876</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Medical College of Wisconsin, Suite 450C, 999 North 92nd Street, Wauwatosa, Milwaukee, WI 53226 USA.</Affiliation><Identifier Source="GRID">grid.30760.32</Identifier><Identifier Source="ISNI">0000 0001 2111 8460</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Jocelyn Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Children's Hospital of Michigan, Detroit, MI USA.</Affiliation><Identifier Source="GRID">grid.414154.1</Identifier><Identifier Source="ISNI">0000 0000 9144 1055</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Central Michigan University College of Medicine, Mount Pleasant, MI USA.</Affiliation><Identifier Source="GRID">grid.253856.f</Identifier><Identifier Source="ISNI">0000 0001 2113 4110</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI USA.</Affiliation><Identifier Source="GRID">grid.254444.7</Identifier><Identifier Source="ISNI">0000 0001 1456 7807</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Infect Dis Rep</MedlineTA><NlmUniqueID>100888983</NlmUniqueID><ISSNLinking>1523-3847</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Management</Keyword><Keyword MajorTopicYN="N">Pediatrics</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Conflict of InterestDr. Frank Zhu declares that he has no conflict of interest.&#xa0;Dr. Jocelyn Ang has participated as a site principal investigator for Eli Lilly and Company Study: J2W-MC PYAB/Addendum 2 (pediatric COVID-19 Study addendum), Eli Lilly and Company's Baricitinib Pediatric COVID-19 Study, from F. Hoffmann-La Roche Ltd 's Tocilizumab Pediatric COVID-19 Study, Regeneron Pharmaceuticals, Inc. 's SARS CoV2 Monoclonal Antibodies Pediatric COVID-19 Study and site co-investigator for Gilead's Remdesivir Pediatric COVID-19 study. Her employer received institutional funds associated with these research projects.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35431658</ArticleId><ArticleId IdType="pmc">PMC8996502</ArticleId><ArticleId IdType="doi">10.1007/s11908-022-00779-0</ArticleId><ArticleId IdType="pii">779</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahase E. COVID-19: WHO declares pandemic because of &#x201c;alarming levels&#x201d; of spread, severity, and inaction. BMJ, 2020;368:m1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">32165426</ArticleId></ArticleIdList></Reference><Reference><Citation>Children and COVID-19. State-level data report. February 12, 2022; Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.</Citation></Reference><Reference><Citation>Ladhani SN, et al. COVID-19 in children: analysis of the first pandemic peak in England. Arch Dis Child. 2020;105(12):1180&#x2013;1185. doi: 10.1136/archdischild-2020-320042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-320042</ArticleId><ArticleId IdType="pmc">PMC7431771</ArticleId><ArticleId IdType="pubmed">32796006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Arch Med Res. 2022;53(1):1&#x2013;8. doi: 10.1016/j.arcmed.2021.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.07.002</ArticleId><ArticleId IdType="pmc">PMC8257427</ArticleId><ArticleId IdType="pubmed">34311990</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsohime F, et al. COVID-19 infection prevalence in pediatric population: etiology, clinical presentation, and outcome. J Infect Public Health. 2020;13(12):1791&#x2013;1796. doi: 10.1016/j.jiph.2020.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.10.008</ArticleId><ArticleId IdType="pmc">PMC7574780</ArticleId><ArticleId IdType="pubmed">33127335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Q, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911&#x2013;919. doi: 10.1016/S1473-3099(20)30287-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30287-5</ArticleId><ArticleId IdType="pmc">PMC7185944</ArticleId><ArticleId IdType="pubmed">32353347</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126&#x2013;2128. doi: 10.1016/S0140-6736(21)02758-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02758-6</ArticleId><ArticleId IdType="pmc">PMC8640673</ArticleId><ArticleId IdType="pubmed">34871545</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, et al. Critical review of the scientific evidence and recommendations in COVID-19 management guidelines. Open Forum Infect Dis, 2021;8(8):ofab376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8360242</ArticleId><ArticleId IdType="pubmed">34395712</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19. Treatment guidelines: special considerations in children. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/special-populations/children/.</Citation></Reference><Reference><Citation>Jackson WM, et al. COVID-19 in pediatric patients: a systematic review. J Neurosurg Anesthesiol. 2022;34(1):141&#x2013;147. doi: 10.1097/ANA.0000000000000803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ANA.0000000000000803</ArticleId><ArticleId IdType="pubmed">34870638</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, et al. Characteristics of hospitalized children with SARS-CoV-2 in the New York City metropolitan area. Hosp Pediatr. 2021;11(1):71&#x2013;78. doi: 10.1542/hpeds.2020-001917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/hpeds.2020-001917</ArticleId><ArticleId IdType="pubmed">33033078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E, et al.&#xa0;Sudden anosmia and ageusia in a child: a COVID-19 case report. Otolaryngol Case Rep.&#xa0;2021;18:100267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7825856</ArticleId><ArticleId IdType="pubmed">34957358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak PQ, et al. Anosmia and ageusia: not an uncommon presentation of COVID-19 infection in children and adolescents. Pediatr Infect Dis J. 2020;39(8):e199&#x2013;e200. doi: 10.1097/INF.0000000000002718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002718</ArticleId><ArticleId IdType="pubmed">32516281</ArticleId></ArticleIdList></Reference><Reference><Citation>King JA, et al. Symptoms associated with a positive result for a swab for SARS-CoV-2 infection among children in Alberta. CMAJ. 2021;193(1):E1&#x2013;E9. doi: 10.1503/cmaj.202065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.202065</ArticleId><ArticleId IdType="pmc">PMC7774482</ArticleId><ArticleId IdType="pubmed">33234533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun&#x4ab; EM, et al. Pediatric croup during the COVID-19 omicron variant surge. medRxiv. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Andina, D, et al. Skin manifestations of COVID-19 in children: part 1. Clin Exp Dermatol. 2021;46(3):444&#x2013;450. Excellent review with images of cutaneous manifestations of COVID-19 in children.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9275402</ArticleId><ArticleId IdType="pubmed">33180982</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Andina D, et al.&#xa0;Skin manifestations of COVID-19 in children: part 3. Clin Exp Dermatol. 2021;46(3):462&#x2013;472. Excellent review with images of cutaneous manifestations of COVID-19 in children.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753282</ArticleId><ArticleId IdType="pubmed">33207021</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Andina D, et al. Skin manifestations of COVID-19 in children: part 2. Clin Exp Dermatol, 2021;46(3):451&#x2013;461. Excellent review with images of cutaneous manifestations of COVID-19 in children.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9275399</ArticleId><ArticleId IdType="pubmed">33166429</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, et al.&#xa0;Epidemiology of COVID-19 among children in China. Pediatrics.&#xa0;2020;145(6).</Citation><ArticleIdList><ArticleId IdType="pubmed">32179660</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRovere KL, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021;78(5):536&#x2013;547. doi: 10.1001/jamaneurol.2021.0504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.0504</ArticleId><ArticleId IdType="pmc">PMC7936352</ArticleId><ArticleId IdType="pubmed">33666649</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; Woodruff RC, et al. Risk factors for severe COVID-19 in children. Pediatrics.&#xa0;2021. Excellent review of risk factors for severe COVID-19 disease in pediatrics.</Citation></Reference><Reference><Citation>&#x2022; Whittaker E, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA&#xa0;2020;324(3):259&#x2013;269. The first major case series of MIS-C with comparison of laboratory values with a historical cohort of Kawasaki disease.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, et al. Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: a systematic review of published case studies. Transl Pediatr. 2021;10(1):121&#x2013;135. doi: 10.21037/tp-20-188.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tp-20-188</ArticleId><ArticleId IdType="pmc">PMC7882293</ArticleId><ArticleId IdType="pubmed">33633944</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooq A, et al. Multisystem inflammatory syndrome in children and adolescents (MIS-C) under the setting of COVID-19: a review of clinical presentation, workup and management. Infect Dis (Auckl) 2021;14:11786337211026642. doi: 10.1177/11786337211026642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11786337211026642</ArticleId><ArticleId IdType="pmc">PMC8221672</ArticleId><ArticleId IdType="pubmed">34220204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu EY, Campbell MJ. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) following COVID-19. Curr Cardiol Rep. 2021;23(11):168. doi: 10.1007/s11886-021-01602-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-021-01602-3</ArticleId><ArticleId IdType="pmc">PMC8486157</ArticleId><ArticleId IdType="pubmed">34599465</ArticleId></ArticleIdList></Reference><Reference><Citation>Radia T, et al. Multi-system inflammatory syndrome in children &amp; adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417920</ArticleId><ArticleId IdType="pubmed">32891582</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Feldstein LR, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med&#xa0;2020;383(4):334&#x2013;346. This is the most comprehensive report on epidemiology, clinical course of MIS-C in the USA. This paper has an excellent description of the clinical characteristics of pediatric patients with MIS-C.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufort EM, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347&#x2013;358. doi: 10.1056/NEJMoa2021756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021756</ArticleId><ArticleId IdType="pmc">PMC7346766</ArticleId><ArticleId IdType="pubmed">32598830</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Henderson LA, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol.&#xa0;2022.&#xa0;Official ACR guidelines for management of MIS-C.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011620</ArticleId><ArticleId IdType="pubmed">35118829</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatr Infect Dis J. 2021;40(12):e482-e487. Review of relatively sparse long COVID data in children.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. February 18, 2022; Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.</Citation></Reference><Reference><Citation>CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. February 20, 2022; Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.</Citation></Reference><Reference><Citation>CDC. COVID-19 vaccines for moderately or severely immunocompromised people. February 12, 2022; Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.</Citation></Reference><Reference><Citation>CDC. COVID-19 vaccine booster shots. February 18, 2022]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html?s_cid=11706:cdc%20covid%20vaccine%20booster%20guidelines:sem.https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html?s_cid=11706:cdc%20covid%20vaccine%20booster%20guidelines:sem.ga:p:RG:GM:gen:PTN:FY22.</Citation></Reference><Reference><Citation>&#x2022; Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020. 383(27):2603&#x2013;2615. Review of safety and efficacy data on Pfizer vaccination.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW, Jr, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761&#x2013;1773. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35&#x2013;46. doi: 10.1056/NEJMoa2116298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116298</ArticleId><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster ME, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331&#x2013;340. doi: 10.1001/jama.2021.24110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Adverse events among children ages 5&#x2013;11 years after COVID-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS). February 20, 2022; Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-12-16/05-COVID-Su-508.pdf.</Citation></Reference><Reference><Citation>Truong DT, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation. 2022;145(5):345&#x2013;356. doi: 10.1161/CIRCULATIONAHA.121.056583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056583</ArticleId><ArticleId IdType="pubmed">34865500</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. March 2, 2020 February 12, 2022; Available from: https://www.who.int/publications/i/item/10665-331501.</Citation></Reference><Reference><Citation>van Kasteren PB, et al.&#xa0;Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol. 2020;128:104412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206434</ArticleId><ArticleId IdType="pubmed">32416600</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. February 12, 2022; Available from: https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html.</Citation></Reference><Reference><Citation>Jamal AJ, et al. Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infect Control Hosp Epidemiol. 2021;42(8):1001&#x2013;1003. doi: 10.1017/ice.2020.1326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2020.1326</ArticleId><ArticleId IdType="pmc">PMC7750656</ArticleId><ArticleId IdType="pubmed">33203496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallett S, et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med. 2020;18(1):346. doi: 10.1186/s12916-020-01810-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01810-8</ArticleId><ArticleId IdType="pmc">PMC7609379</ArticleId><ArticleId IdType="pubmed">33143712</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KA, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81(3):357&#x2013;371. doi: 10.1016/j.jinf.2020.06.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.067</ArticleId><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Rhee C. et al.&#xa0;Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis, 2021;72(8):1467&#x2013;1474. Review which summarizes evidence-to-date on the duration of infectivity of SARS-CoV-2 and when it is safe to discontinue isolation precautions.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499497</ArticleId><ArticleId IdType="pubmed">33029620</ArticleId></ArticleIdList></Reference><Reference><Citation>Owusu D, et al. Persistent SARS-CoV-2 RNA shedding without evidence of infectiousness: a cohort study of individuals with COVID-19. J Infect Dis. 2021;224(8):1362&#x2013;1371. doi: 10.1093/infdis/jiab107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab107</ArticleId><ArticleId IdType="pmc">PMC7989388</ArticleId><ArticleId IdType="pubmed">33649773</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen JJA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat Commun. 2021;12(1):267. doi: 10.1038/s41467-020-20568-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20568-4</ArticleId><ArticleId IdType="pmc">PMC7801729</ArticleId><ArticleId IdType="pubmed">33431879</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586&#x2013;2588. doi: 10.1056/NEJMc2031670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031670</ArticleId><ArticleId IdType="pmc">PMC7722690</ArticleId><ArticleId IdType="pubmed">33259154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahbudak Bal Z, et al. The longest infectious virus shedding in a child infected with the G614 strain of SARS-CoV-2. Pediatr Infect Dis J. 2021;40(7):e263&#x2013;e265. doi: 10.1097/INF.0000000000003158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003158</ArticleId><ArticleId IdType="pubmed">33990523</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Interim guidance for antigen testing for SARS-CoV-2. February 12, 2022; Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html.</Citation></Reference><Reference><Citation>Dinnes J, et al.&#xa0;Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3:CD013705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078597</ArticleId><ArticleId IdType="pubmed">33760236</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; CDC. Overview of testing for SARS-CoV-2, the virus that causes COVID-19. [cited 2022; Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html#TestingInfection. CDC guidance of SARS-CoV-2 testing.</Citation></Reference><Reference><Citation>Qu J, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020;71(16):2255&#x2013;2258. doi: 10.1093/cid/ciaa489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa489</ArticleId><ArticleId IdType="pmc">PMC7197626</ArticleId><ArticleId IdType="pubmed">32337590</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, et al.&#xa0;Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science.&#xa0;2021;371(6529).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Interim guidelines for COVID-19 antibody testing. Februrary 12, 2022; Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.</Citation></Reference><Reference><Citation>Letizia AG, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9(7):712&#x2013;720. doi: 10.1016/S2213-2600(21)00158-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00158-2</ArticleId><ArticleId IdType="pmc">PMC8049591</ArticleId><ArticleId IdType="pubmed">33865504</ArticleId></ArticleIdList></Reference><Reference><Citation>Letizia AG, et al. SARS-CoV-2 seropositivity among US marine recruits attending basic training, United States, spring-fall 2020. Emerg Infect Dis. 2021;27(4):1188&#x2013;1192. doi: 10.3201/eid2704.204732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2704.204732</ArticleId><ArticleId IdType="pmc">PMC8007328</ArticleId><ArticleId IdType="pubmed">33529569</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A, et al.&#xa0;Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol.&#xa0;2020; 58(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587101</ArticleId><ArticleId IdType="pubmed">32826322</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey RA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181(5):672&#x2013;679. doi: 10.1001/jamainternmed.2021.0366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.0366</ArticleId><ArticleId IdType="pmc">PMC7905701</ArticleId><ArticleId IdType="pubmed">33625463</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VJ, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) Lancet. 2021;397(10283):1459&#x2013;1469. doi: 10.1016/S0140-6736(21)00675-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00675-9</ArticleId><ArticleId IdType="pmc">PMC8040523</ArticleId><ArticleId IdType="pubmed">33844963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley SF, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533&#x2013;540. doi: 10.1056/NEJMoa2034545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034545</ArticleId><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogega CO, et al.&#xa0;Durable SARS-CoV-2 B cell immunity after mild or severe disease. medRxiv. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011891</ArticleId><ArticleId IdType="pubmed">33571162</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 19. February 12, 2022; Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005517/Technical_Briefing_19.pdf.</Citation></Reference><Reference><Citation>Altarawneh HN. et al. Protection against the omicron variant from previous SARS-CoV-2 infection. New England J Med. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849180</ArticleId><ArticleId IdType="pubmed">35139269</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020;58(7):1135&#x2013;1138. doi: 10.1515/cclm-2020-0272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0272</ArticleId><ArticleId IdType="pubmed">32172227</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry BM, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020;81:1&#x2013;8. doi: 10.1016/j.clinbiochem.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7251358</ArticleId><ArticleId IdType="pubmed">32473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Das KM, et al. Comparison of chest radiography and chest CT for evaluation of pediatric COVID-19 pneumonia: does CT add diagnostic value? Pediatr Pulmonol. 2021;56(6):1409&#x2013;1418. doi: 10.1002/ppul.25313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.25313</ArticleId><ArticleId IdType="pmc">PMC8014659</ArticleId><ArticleId IdType="pubmed">33631061</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. February 12, 2022; Available from: https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection#:~:text=The%20Centers%20for%20Disease%20Control,19%20on%20CXR%20or%20CT.</Citation></Reference><Reference><Citation>Foust AM, et al. Practical guide for pediatric pulmonologists on imaging management of pediatric patients with COVID-19. Pediatr Pulmonol. 2020;55(9):2213&#x2013;2224. doi: 10.1002/ppul.24870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.24870</ArticleId><ArticleId IdType="pmc">PMC7283678</ArticleId><ArticleId IdType="pubmed">32462724</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiotos K, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc. 2021;10(1):34&#x2013;48. doi: 10.1093/jpids/piaa115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa115</ArticleId><ArticleId IdType="pmc">PMC7543452</ArticleId><ArticleId IdType="pubmed">32918548</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; CDC. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers. February 12, 2022; Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. CDC guidance on risk factors for progression to severe COVID-19 disease.</Citation></Reference><Reference><Citation>Astra Zeneca. EVUSHELD long-acting antibody combination retains neutralizing activity against omicron variant in studies from Oxford and Washington universities. 2021 [cited 2022; Available from: https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities.html.</Citation></Reference><Reference><Citation>&#x2022;&#x2022; NIH. Therapeutic management of nonhospitalized adults with COVID-19. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/. NIH guidelines which provide comprehensive review of management of nonhospitalized adult patients.</Citation></Reference><Reference><Citation>&#x2022;&#x2022; AAP. Management strategies in children and adolescents with mild to moderate COVID-19. February 12, 2022; Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/. AAP guidance with comprehensive management of pediatric mild to moderate COVID-19 disease.</Citation></Reference><Reference><Citation>FDA. Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. February 12, 2022; Available from: https://www.fda.gov/media/149534/download.</Citation></Reference><Reference><Citation>FDA. Fact sheet for healthcare providers: emergency use authroization (EUA) of bebtelovimab. February 18, 2022; Available from: http://www.fda.gov/media/156151/download.</Citation></Reference><Reference><Citation>FDA. Evusheld EUA letter of authorization. February 12, 2022; Available from: https://www.fda.gov/media/154704/download.</Citation></Reference><Reference><Citation>FDA. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. February 12, 2022; Available from: https://www.fda.gov/media/155050/download.</Citation></Reference><Reference><Citation>NIH. The COVID-19 treatment guidelines panel&#x2019;s statement on potential drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/.</Citation></Reference><Reference><Citation>Jayk Bernal A, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509&#x2013;520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; NIH. The COVID-19 treatment guidelines panel&#x2019;s statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/. NIH guidelines which provide comprehensive review of management of high-risk nonhospitalized adult patients.</Citation></Reference><Reference><Citation>&#x2022; Gottlieb RL, et al.&#xa0;Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386(4):305&#x2013;315. Recent publication demonstrating effectiveness of early remdesivir to prevent progression to severe COVID-19 disease.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Clinical spectrum of SARS-CoV-2 infection. February 20, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.</Citation></Reference><Reference><Citation>Attaway, AH, et al. Severe COVID-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436.</Citation><ArticleIdList><ArticleId IdType="pubmed">33692022</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Remdesivir. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/.</Citation></Reference><Reference><Citation>Beigel JH, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med. 2020;383(19):1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium WHOST, et al. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med.&#xa0;2021;384(6):497&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader F, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209&#x2013;221. doi: 10.1016/S1473-3099(21)00485-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00485-0</ArticleId><ArticleId IdType="pmc">PMC8439621</ArticleId><ArticleId IdType="pubmed">34534511</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Therapeutic management of hospitalized adults with COVID-19. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/.</Citation></Reference><Reference><Citation>Ali K, et al.&#xa0;Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ&#xa0;2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863204</ArticleId><ArticleId IdType="pubmed">35045989</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Special considerations in children. February 12, 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/special-populations/children/.</Citation></Reference><Reference><Citation>Group RC, et al.&#xa0;Dexamethasone in hospitalized patients with COVID-19 N Engl J Med 2021;384(8):693-704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, et al.&#xa0;Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone. Clin Infect Dis. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513400</ArticleId><ArticleId IdType="pubmed">34420051</ArticleId></ArticleIdList></Reference><Reference><Citation>Benfield T, et al.&#xa0;Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021;73(11):2031&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344480</ArticleId><ArticleId IdType="pubmed">34111274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffari E, et al.&#xa0;Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis.&#xa0;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402660</ArticleId><ArticleId IdType="pubmed">34596223</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Marrone A, et al.&#xa0;Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study. Clin Infect Dis.&#xa0;2022. Recent publication demonstrating improved mortality through the combination of remdesivir and dexamethasone over dexamethasone alone.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807307</ArticleId><ArticleId IdType="pubmed">35084022</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators R-C, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384(16):1491&#x2013;1502. doi: 10.1056/NEJMoa2100433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Lancet 2021;397(10285):1637-1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi VC, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407&#x2013;1418. doi: 10.1016/S2213-2600(21)00331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitworth H, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021;138(2):190&#x2013;198. doi: 10.1182/blood.2020010218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020010218</ArticleId><ArticleId IdType="pmc">PMC8079262</ArticleId><ArticleId IdType="pubmed">33895804</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Goldenberg NA, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost.&#xa0;2020;18(11):3099&#x2013;3105. Consensus-based recommendations for anticoagulation for the management pediatric COVID-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906345</ArticleId><ArticleId IdType="pubmed">33174388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>